NEW YORK (GenomeWeb) – Illumina today announced it has acquired regulatory and quality consulting firm Myraqa for an undisclosed amount.

Based in Redwood Shores, Calif., Myraqa was founded in 1998 and specializes in in vitro diagnostics, particularly companion diagnostics, and focuses on regulatory strategy and application support, including premarket approvals, pre-submissions, investigational device exemptions, 510(k)s, de novo 510(k)s, and European Union technical files, Illumina said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.